2015 San Antonio Breast Cancer Symposium Coverage

By on December 14th, 2015 Categories: Research News

We’re proud to bring you our coverage of the 2015 San Antonio Breast Cancer Symposium! Below you can find our coverage of breast cancer study results presented December 8-12, 2015 in San Antonio, TX. Keep checking this page for updates in Research News and podcasts with our experts!

[Editor’s Note: Updates will be added to the top of this page.]



Dec 22, 2015

Treating Residual Disease With Xeloda Improves Survival in Women With Early-Stage, HER2-Negative Disease

Women diagnosed with early-stage, HER2-negative breast cancer with residual disease who were treated with Xeloda after surgery had better survival compared to women who didn’t get chemotherapy after surgery.


Dec 14, 2015

Kadcyla Improves Survival in Women Diagnosed With Metastatic, HER2-Positive Disease That’s Stopped Responding to Herceptin and Tykerb

The TH3RESA study found that Kadcyla improved overall survival in women diagnosed with metastatic, HER2-positive breast cancer that had stopped responding to Herceptin and Tykerb compared to the women’s doctors’ treatment of choice.


Dec 12, 2015

Arimidex or Tamoxifen Reduce Recurrence Risk After DCIS Equally Well in Postmenopausal Women, Choice Depends on Age, Side Effects

Two studies presented at the 2015 San Antonio Breast Cancer Symposium looked at the effectiveness and side effects of Arimidex and tamoxifen to reduce recurrence risk after DCIS surgery and radiation in postmenopausal women. The studies found that the medicines reduced the risk of recurrence about the same amount, but there were differences in side effects.

Chief Medical Officer Marisa Weiss, M.D. talks about these studies:


Dec 10, 2015

Study Suggests Premenopausal Women With Certain Type of Breast Cancer Don’t Benefit From Chemotherapy

Luminal A breast cancer is cancer that is estrogen-receptor positive and/or progesterone-receptor positive, HER2-negative, and has low levels of the protein Ki-67, which helps control how fast cancer cells grow. Research presented at the 2015 San Antonio Breast Cancer Symposium suggests that premenopausal women diagnosed with luminal A breast cancer have the same disease-free survival rates whether or not they receive chemotherapy after surgery.


Dec 10, 2015

Prolia Reduces Recurrence Risk of Hormone-Receptor-Positive Disease in Women Taking Aromatase Inhibitors

Prolia is a targeted therapy used to treat bone loss in women taking aromatase inhibitors as part of their breast cancer treatment. A study presented at the 2015 San Antonio Breast Cancer Symposium has found that Prolia also reduced recurrence risk for postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer taking an aromatase inhibitor.

Dr. Marisa Weiss shares her perspective about this study:


Dec 10, 2015

Triple-Negative Disease May Have New Treatment Option

Two studies presented at the 2015 San Antonio Breast Cancer Symposium suggest that adding carboplatin to the standard presurgery chemotherapy regimen may improve outcomes for women diagnosed with triple-negative disease.

Dr. Marisa Weiss talks more about the first study:


Dr. Weiss also discusses the second study:


Dec 10, 2015

Lumpectomy Plus Radiation May Offer Survival Benefits for Early-Stage Disease

Many studies from the 1970s showed that lumpectomy plus radiation to treat early-stage breast cancer offered the same survival rates as mastectomy. So it was recommended that lumpectomy plus radiation be preferred over mastectomy to treat early-stage disease. Over the last several years, some studies suggested that lumpectomy plus radiation offered better survival than mastectomy for early-stage disease cancer, but the follow-up time was only 5 years. Now a study with 10 years of follow-up also suggests that lumpectomy plus radiation may offer survival benefits for some women diagnosed with early-stage disease.

Dr. Marisa Weiss explains what this means for you if you’re making surgery decisions:

Stay tuned to this page for more coverage on the way!

Claire Nixon, Editorial Director — Claire directs a team of writers, researchers, content managers, and physicians through the creation of high-integrity web content. She brings 20 years of experience in health communications and journalism to the Breastcancer.org team, as well as the lens of the patient – she was treated for breast cancer in 1998 and again in 2012. In her off-time, Claire enjoys creative writing, independent films, meditation, and the ocean.


Leave a Comment

To keep our Community safe, you must register to start a topic, post a reply, or use the Chat Rooms. If you are an existing member of our Discussion Boards, you can log in to access your account. Please review our Privacy Statement before registering.

Register now or log in to your account.

Back to top

Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.

Breastcancer.org 120 East Lancaster Avenue, Suite 201 Ardmore, PA 19003

© 2022 Breastcancer.org - All rights reserved.